Head to head
DRUGS MADE IN AMERICA ACQ II CORP vs Vylor Inc
Side-by-side on the measures that matter, with a plain-English read. Full detail: DMII · VYLR
DMII
DRUGS MADE IN AMERICA ACQ II CORP
10.19+0.00%
1-year price shape — not enough history yet
Quant Rating D · 52/100
vs
VYLR
Vylor Inc
74.37+1.89%
1-year price shape — not enough history yet
Quant Rating C · 0/100
DRUGS MADE IN AMERICA ACQ II CORP edges it on the scoreable measures. DRUGS MADE IN AMERICA ACQ II CORP has the highest Quant Rating (52); DRUGS MADE IN AMERICA ACQ II CORP trades cheapest on trailing earnings.
| DMII | VYLR | |
|---|---|---|
| Snapshot | ||
| Sector | Shell Companies | Shell Companies |
| Last price | 10.19 | 74.37 |
| Change today | +0.00% | +1.89% |
| 1-year return | -- | -- |
| Market cap | $649.10M | $49.62B |
| 52-week range | 9.86 – 10.33 | 65.00 – 75.49 |
| Valuation | ||
| P/E (TTM) | 34.90 | 104.89 |
| P/E percentile, own 5-yr range | 60th | 100th |
| P/B | 1.31 | 3.27 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 0.15 | 0.56 |
| Net profit (TTM) | $9.56M | $376.30M |
| Revenue (TTM) | $0 | -- |
| Revenue growth (YoY) | -- | +12.4% |
| Gross margin | -- | 54.5% |
| Operating margin | -- | 18.7% |
| Net margin | -- | 4.5% |
| Free cash flow (TTM) | $-1.28M | -- |
| Ownership & sentiment | ||
| Institutional ownership | 76.9% | 0.1% |
| Insider activity (12mo) | 6 buy / 2 sell | 37 buy / 12 sell |
| Short interest (% of float) | 0.2% | -- |
| Analyst consensus | -- | 100% buy (3) |
| Analyst price target | -- | $79 (+6%) |
| StockVane view | ||
| StockVane Quant Rating | D (52) | C (0) |
| Company | ||
| Employees | 2 | -- |
| Founded | -- | -- |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.